The Indonesia Continuous Glucose Monitoring (CGM) market is forecast to grow at a CAGR of 17.6%, reaching USD 4.6 million in 2031 from USD 2.1 million in 2026.
Continuous sugar monitoring (CGM), sometimes referred to as continuous glucose monitoring, automatically monitors blood glucose throughout the day. Making more educated choices about maintaining daily medication use, a healthy diet, and physical activity can be aided with real-time glucose monitoring. A small sensor used in CGM is implanted beneath the skin, often on the arm or abdomen. The sensor picks up interstitial glucose, which is present in the intercellular fluid. The sensor examines the glucose level every few minutes, and wireless data transmission sends the results to a monitor.
Moreover, the closed-loop bionic/artificial pancreas has been given a blueprint because of CGMS-based technologies. Thus, businesses that manufacture glucose monitoring devices concentrate largely on creating novel and cutting-edge CGMS. It has several applications for healthcare settings (hospital ICUs, diagnostic centers, and clinics), for all age groups, and geographical locations. A growing awareness of diabetes preventative care, new product debuts, government efforts, and the CGM device market are the major market drivers for the CGM Market.
In Indonesia, diabetes is seen as a serious health issue and has raised concerns. To address the rising number of diabetics in Indonesia, diabetes professionals have developed suggestions for avoiding and controlling the disease. To avoid major side effects such as neuropathy, nephropathy, retinopathy, microvascular disease, and cardiovascular disease, diabetes control is essential. These treatments are only accessible because of diabetes education initiatives that encourage self-care. In Indonesia, healthcare practitioners provide diabetes education programs. A lack of skilled healthcare professionals (HCPs) to teach people with diabetes is caused by the limited availability of certified diabetic educators in Indonesia.
The market for continuous glucose monitoring systems in Indonesia has grown significantly as a result of the rising prevalence of diabetes and increased R&D. Diabetes cases are on the rise in the nation, which may be related to people's bad eating patterns, sedentary lifestyles, and lack of exercise. The market does, however, confront certain obstacles to expansion, such as problems with government permission and regulation.
Increasing patients with Type-1 diabetes in Indonesia will lead to a surge in growth.
Indonesia is the eighth most diabetic country in the world. The national government's insurance program mostly covers people's health costs in Indonesia. Medical necessities, including consultations, hospital stays, insulin, and needles, are covered by government insurance when obtained from specific clinics, hospitals, or approved pharmacies. Type-1 diabetes has been prevailing in the nation, and hence, the use of CGM to conquer this has been growing.
Increasing technological advancements to surge growth.
The market's expansion can also be attributed to the rising medical technology advancements, the expanding use of IT in healthcare, the surge in demand for mobile health (mHealth) applications, supported by the nation's growing internet user population, and the rising use of smart wearables by its citizens. In addition, it is anticipated that the nation's rising health expenditures would open up considerable prospects for market expansion in the years to come.
In February 2023, the Dexcom G6 CGM System was introduced by Dexcom, Inc., a leader in real-time continuous glucose monitoring (CGM) for diabetics.
In May 2022, Abbott got FDA approval for the FreeStyle Libre 3 continuous glucose monitor.
| Report Metric | Details |
|---|---|
| Study Period | 2021 to 2031 |
| Historical Data | 2021 to 2024 |
| Base Year | 2025 |
| Forecast Period | 2026 – 2031 |
| Companies |
|